Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
|Videos|October 4, 2021
Dr. Chang on robot-assisted versus open radical prostatectomies
Author(s)Urology Times staff
“The quality of life overall between the 2 approaches was very similar,” says Peter Chang, MD, PhD.
Advertisement
In this video Peter Chang, MD, PhD, discusses the background and findings of the Journal of Urology study, “Prospective multicenter comparison of open and robotic radical prostatectomy: The PROST-QA/RP2 consortium.” Chang is an assistant professor of surgery at Harvard Medical School and the director of the Prostate Cancer Care Center at Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Advertisement
Related to this article
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Advertisement
Advertisement